Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 9 of 29 for:    neuronetics

Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Neuronetics
Sponsor:
Information provided by (Responsible Party):
Neuronetics
ClinicalTrials.gov Identifier:
NCT02586688
First received: October 23, 2015
Last updated: February 16, 2017
Last verified: February 2017
  Purpose
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).

Condition Intervention
Major Depressive Disorder
Device: Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
Device: Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Device: Open Label Active NeuroStar® TMS

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

Further study details as provided by Neuronetics:

Primary Outcome Measures:
  • Hamilton Depression Rating Scale-24(HAMD24) total score change from baseline value. [ Time Frame: 6 weeks ]

Estimated Enrollment: 100
Study Start Date: October 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Phase I TMS Active
Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
Device: Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
Compare active NeuroStar® coil with sham NeuroStar® coil.
Other Names:
  • TMS
  • NeuroStar®
Sham Comparator: Phase I TMS Sham
Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Device: Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Compare active NeuroStar® coil with sham NeuroStar® coil.
Other Names:
  • TMS
  • NeuroStar®
Phase II Open Label Active TMS
Open label active TMS coil. Open label active NeuroStar® TMS.
Device: Open Label Active NeuroStar® TMS
Open label NeuroStar® coil.
Other Names:
  • TMS
  • NeuroStar®
Phase III Long-Term Follow up TMS Active
Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
Device: Open Label Active NeuroStar® TMS
Open label NeuroStar® coil.
Other Names:
  • TMS
  • NeuroStar®

Detailed Description:

To evaluate the antidepressant effects of daily, active TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder, single or recurrent episode (Phase I).

Secondary:

To evaluate the acute and long term safety of TMS treatment in adolescent MDD subjects.

To evaluate the durability of benefit of TMS treatment over the course of 6 months in subjects who received clinical benefit from acute treatment course(s) (Phase III).

To evaluate the benefit of daily, active, open-label TMS in Phase I subjects who did not receive protocol-defined clinical benefit; as new acute treatment (sham to active) or as extended treatment course (blinded active to open label active) (Phase II).

  Eligibility

Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary diagnosis of unipolar major depressive disorder, in a current major depressive episode, without psychotic features
  • Duration of current episode of depression ≥4 weeks and ≤3 years
  • Clinical Global Impression - Severity of Illness ≥ 4
  • Resistance to antidepressant treatment in a discrete illness episode
  • HAMD24 Item 1 ≥ 2 and total score ≥ 20
  • Subjects able to commit to protocol visit schedule
  • At the end of the baseline visit, subject must have a HAMD24 score of ≥ 18 and change in score may not be ≥ 25% decrease from that seen at the screening visit

Exclusion Criteria:

  • Prior TMS, vagus nerve stimulation (VNS), or electroconvulsive therapy (ECT)
  • Contraindication to TMS
  • Cardiac pacemakers, implanted medication pumps, intracardiac lines
  • History of neurological disorder
  • Unstable medical conditions
  • Any psychiatric disorder, which in the judgement of the Investigator may hinder the subject in completing the procedures required by the study protocol.
  • Significant acute suicide risk
  • Inability to locate and quantify a motor threshold
  • If sexually active female, not on an accepted method of birth control.
  • Diagnoses of the following conditions (current unless otherwise stated):

    • Depression secondary to a general medical condition, or substance induced:
    • Seasonal pattern of depression as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
    • Any psychotic disorder (lifetime), including history of schizophrenia, schizoaffective disorder, other psychosis, psychotic features in this or previous episodes, amnestic disorder,
    • Intellectually disabled,
    • Substance dependence or abuse within the past year (except nicotine or caffeine),
    • Bipolar disorder,
    • Obsessive compulsive disorder (lifetime),
    • Post-traumatic stress disorder (lifetime),
    • Eating disorder (lifetime).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02586688

Contacts
Contact: Melissa Reitenbaugh 610- 640-4202 ext 1039 mreitenbaugh@neuronetics.com
Contact: Denene Finnerty 610 640-4202 ext 1020 dfinnerty@neuronetics.com

Locations
United States, Alabama
Dothan Behavioral Medicine Recruiting
Dothan, Alabama, United States, 36303
Contact: Melinda Vasbinder    334-702-7222 ext 233    mvasbinder@harmonex.us   
Principal Investigator: Emmalynn McDowell, MD         
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90024
Contact: Nikita Vince Cruz    310-825-7471    nvincecruz@mednet.ucla.edu   
Principal Investigator: Andrew Leuchter, MD         
Stanford University Recruiting
Palo Alto, California, United States, 94305
Contact: Jessica Hawkins    650-723-8323    jhawk@stanford.edu   
Principal Investigator: H. Brent Solvason, MD         
United States, Colorado
Rocky Mountain TMS Recruiting
Grand Junction, Colorado, United States, 81501
Contact: Christopher Blackburn    970-697-1020    christopher@tmssolutions.com   
Principal Investigator: Robert Sammons, MD         
United States, Florida
Florida Clinical Practice Association, Inc. Recruiting
Gainesville, Florida, United States, 32606
Contact: Dana Mason    352-273-8540    dmason@ufl.edu   
Principal Investigator: Richard Holbert, MD         
Anchor Neuroscience Recruiting
Pensacola, Florida, United States, 32502
Contact: Whitney Vaughan    850-433-1656 ext 2    wvaughan@anchorneuroscience.com   
Principal Investigator: Pashia Groom, PhD         
United States, Indiana
Beacon Medical Group Recruiting
South Bend, Indiana, United States, 46601
Contact: Toni Riehm    547-647-6584    triehm@beaconhealthsystem.org   
Principal Investigator: Ahmed Elmaadawi, MD         
United States, Kentucky
Integrative Psychiatry Recruiting
Louisville, Kentucky, United States, 40222
Contact: Alex Schrodt    502-930-7881    louisvilletmsstudy@gmail.com   
Principal Investigator: G. Randolph Schrodt, MD         
United States, Maryland
Sheppard Pratt Health System Recruiting
Baltimore, Maryland, United States, 21285
Contact: Jennifer Sklar    410-938-3136    jsklar@sheppardpratt.org   
Principal Investigator: Scott Aaronson, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Tara Johnson    507-255-0761    Johnson.Tara@mayo.edu   
Principal Investigator: Paul Croarkin, MD         
United States, Ohio
University of Cincinnati College of Medicine Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Sara Varney    513-558-2931    varneysa@ucmail.uc.edu   
Principal Investigator: Jeffrey R Strawn, MD         
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Nichole Storey    614-685-8754    Nichole.Storey@osumc.edu   
Contact: Anne-Marie Duchemin    (614) 293-5517      
Principal Investigator: Kevin Reeves, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Morgan Maddox Darcy    843-876-5141    maddoxm@musc.edu   
Principal Investigator: Mark George, MD         
Sponsors and Collaborators
Neuronetics
Investigators
Study Chair: Mark Demitrack, MD Neuronetics
Study Director: Karen Heart Neuronetics
  More Information

Publications:
Responsible Party: Neuronetics
ClinicalTrials.gov Identifier: NCT02586688     History of Changes
Other Study ID Numbers: 44-02219-000
Study First Received: October 23, 2015
Last Updated: February 16, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Neuronetics:
child depression
depression
Transcranial Magnetic Stimulation
Adolescent Major Depressive Disorder
TMS
adolescent depression

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on April 28, 2017